Biocon Limited has announced the commercial launch of its biosimilar, Yesafili™ (aflibercept-jbvf), in the United States. Approved as an interchangeable biosimilar to Regeneron’s Eylea® 2 mg, Yesafili™ targets conditions like age-related macular degeneration. This launch marks a strategic expansion into the significant US ophthalmology market, aiming to increase patient access to vital treatments.
Biocon Announces U.S. Commercial Launch of Yesafili™
Biocon Limited has officially launched its biosimilar product, Yesafili™ (aflibercept-jbvf), in the United States market. This development signifies a major step in the company’s global expansion strategy within the ophthalmology sector.
Key Product Details and Approval
Yesafili™ is an interchangeable biosimilar to Regeneron’s Eylea® 2 mg and is indicated for the treatment of patients with Neovascular (Wet) Age-Related Macular Degeneration (AMD), Macular Edema Following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR). The product received U.S. Food and Drug Administration (FDA) approval and was granted interchangeable designation in May 2024, allowing for pharmacy-level substitution under state laws.
Market Opportunity and Strategic Importance
The U.S. market presents a substantial opportunity, with an estimated 19.8 million Americans living with age-related macular degeneration. Sales of aflibercept reached approximately $5.89 billion in the U.S. in 2023. The launch of Yesafili™ is expected to enhance access to life-changing medicines for patients and strengthen Biocon’s presence in the global biosimilars landscape.
About Biocon Limited
Biocon Limited is a global biopharmaceutical company committed to providing affordable, life-changing medicines worldwide. Headquartered in Bengaluru, India, the company focuses on addressing critical healthcare challenges across chronic and non-communicable diseases through its diverse portfolio of biosimilars and generics. Biocon operates in over 120 countries and has a robust pipeline of biosimilar assets.
Source: BSE
